R&D Reference Number Project Short title Project Full title Recruitment end date
1802593 HOPE-1 A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE II STUDY
TO EVALUATE THE EFFICACY AND SAFETY OF SPX-101 INHALATION
SOLUTION IN SUBJECTS WITH CYSTIC FIBROSIS (HOPE-1 STUDY:
HYDRATION FOR OPTIMAL PULMONARY EFFECTIVENESS)
10/11/2018
1611335 Rituximab versus cyclophosphamide in connective tissue disease-ILD (RECITAL) A randomized, double blind controlled trial comparing rituximab against intravenous cyclophosphamide in connective tissue disease associated interstitial lung disease 31/08/2019
1801561 Living with Cystic Fibrosis (v2) Quality of life measurement in people with cystic fibrosis registered with the UK CF Registry 01/09/2019
1804573 TRAIL1 A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Safety, Tolerability and Efficacy of Pirfenidone in Patients with Rheumatoid Arthritis Interstitial Lung Disease 31/10/2019
1507115 ILD Genetics – Identification of disease susceptibility genes and autoantibodies associated with the development and clinical characteristics of interstitial lung disease (ILD) in patients with and without proven connective tissue diseases (CTDs). ILD Genetics 01/03/2021
1507118 Adjuvant Steroids in Adults with Pandemic Influenza Early low dose steroids for adults admitted to hospital with influenza-like illness during a pandemic: a randomised placebo controlled trial 01/05/2025